Smruthi Organics Limited announced that its Unit II in Solapur, Maharashtra, has been classified as complying with Good Manufacturing Practices (GMP) with corrective action by the Brazilian Health Regulatory Agency (ANVISA). This classification follows an inspection conducted from June 7 to June 11, 2026.

The regulatory report indicates that the establishment meets conditions for certification regarding the inspected active pharmaceutical ingredient. While this marks a significant step in the certification process, the company clarified that the final GMP certificate has not yet been received as of October 21, 2026.

Inspection Details and Status

The intimation was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The inspection covered the facility located at Chincholi, Taluka Mohol, District Solapur. The specific status assigned is "Complies with Good Manufacturing Practices with Corrective Action," which implies that while the facility meets core standards, certain corrective measures are required before full certification is issued.

What the Numbers Show

The disclosure highlights a procedural milestone rather than a financial event. The key metric here is the regulatory status itself: moving from inspection to a conditional compliance classification reduces uncertainty for export operations into Brazil. However, the absence of the final certificate means the operational impact on revenue or export volumes remains unquantified until the formal documentation is secured.

Smruthi Organics Limited reported a significant turnaround in its financial performance for the first quarter of FY27, with net profit after tax (PAT) rising to ₹287.81 lakh for the quarter ended June 30, 2026. This marks a substantial improvement from the net loss of ₹109.54 lakh recorded in Q1FY26. The positive result was primarily driven by strong performance in its Bulk Drugs and Intermediates (API) division and the strategic discontinuance of its Formulations Marketing Division.

The Board of Directors approved the unaudited financial results at a meeting held on August 10, 2026, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Gokhale & Sathe Chartered Accountants, who issued an unmodified moderate assurance report. The filing highlights that the Formulations Division was classified as a discontinued operation effective May 13, 2026, with its residual assets under recovery.

Financial Performance Highlights

Revenue from operations grew by 55.4% year-on-year to ₹2930.22 lakh in Q1FY27, up from ₹1885.31 lakh in Q1FY26. This growth outpaced the previous quarter’s revenue of ₹2905.45 lakh, indicating sustained momentum. Total income stood at ₹2932.78 lakh, including other income of ₹2.56 lakh.

The company managed to control expenses effectively despite the revenue surge. Cost of materials consumed increased to ₹1392.45 lakh from ₹1200.78 lakh in the prior year, reflecting higher production volumes. Employee benefit expenses remained stable at ₹449.02 lakh. Notably, finance costs decreased to ₹31.10 lakh from ₹46.18 lakh in Q1FY26, contributing to improved profitability. Depreciation and amortization expenses were recorded at ₹160.15 lakh.

Segment-Wise Analysis

With the discontinuance of the Formulations Marketing Division, the API segment now represents the sole operating segment of the company. The API division generated revenue of ₹2931.96 lakh in Q1FY27, up from ₹1893.58 lakh in Q1FY26. The segment’s result before interest and taxes (EBIT) improved dramatically to ₹419.64 lakh from a loss of ₹53.21 lakh in the corresponding period last year.

The discontinued Formulations Division reported a loss before tax of ₹8.82 lakh in Q1FY27, compared to a loss of ₹7.17 lakh in Q1FY26. As per Ind AS 105, the results of this division are presented separately. Unallocable costs of ₹72.57 lakh and interest expense of ₹22.09 lakh related to the discontinued division have been presented within the API segment for the current quarter, while comparatives have not been restated.

What the Numbers Show

The most critical insight from Smruthi Organics’ Q1FY27 results is the operational efficiency gained by shedding the loss-making Formulations unit. While revenue growth of 55% is robust, the shift in profit dynamics is more pronounced: the company moved from a pre-tax loss of ₹148.16 lakh to a profit of ₹392.88 lakh. This turnaround was not solely due to top-line growth but also benefited from reduced finance costs and the elimination of drag from the Formulations segment. The API segment’s EBIT margin expanded significantly, suggesting that the core business is scaling efficiently. Investors should monitor whether the integration of unallocable costs into the API segment will impact future margin visibility or if these costs will decline as the Formulations wind-down completes.